Feasibility, safety, efficacy and potential scaling-up of sofosbuvir-based HCV treatment in Central and West Africa: (TAC ANRS 12311 trial).

doi:10.1038/s41598-024-57013-1

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Feasibility, safety, efficacy and potential scaling-up of sofosbuvir-based HCV treatment in Central and West Africa: (TAC ANRS 12311 trial).

Scientific reports - 3 May 2024

Lacombe Karine, Moh Raoul, Chazallon Corine, Lemoine Maud, Sylla Babacar, Fadiga Fatoumata, Le Carrou Jerôme, Marcellin Fabienne, Kouanfack Charles, Ciaffi Laura, Sartre Michelle Tagni, Sida Magloire Biwole, Diallo Alpha, Gozlan Joel, Seydi Moussa, Cissé Viviane, Danel Christine, Girard Pierre Marie, Toni Thomas d'Aquin, Minga Albert, Boyer Sylvie, Carrieri Patrizia, Attia Alain

Abstract excerpt

Access to Hepatis C treatment in Sub-Saharan Africa is a clinical, public health and ethical concern. The multi-country open-label trial TAC ANRS 12311 allowed assessing the feasibility, safety, efficacy of a specific care model of HCV treatment and retreatment in patients with hepatitis C in Sub Saharan Africa. Between November 2015 and March 2017, with follow-up until mid 2019, treatment-naïve patients with HCV...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Africa, Central

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Africa, Western

Share to Aminoisobutyric Acids

Share to Benzopyrans

Share to Fluorenes

Share to Heterocyclic Compounds, 4 or More Rings

Share to Lactams, Macrocyclic

Share to Quinoxalines

Source

Open in PubMed Open full text

Identifiers

PMID: 38702350
DOI: 10.1038/s41598-024-57013-1
PMCID: PMC11068860

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Feasibility, safety, efficacy and potential scaling-up of sofosbuvir-based HCV treatment in Central and West Africa: (TAC ANRS 12311 trial).PMID 38702350Read ↗

Feasability and effectiveness of scaling up hepatitis-C treatment in West and Central Africa: the TAC ANRS 12311 clinical trialSemantic proximity Read ↗

Hepatitis C in sub-Saharan Africa: the current status and recommendations for achieving elimination by 2030.Semantic proximity Read ↗

Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts.Semantic proximity Read ↗

A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial.Semantic proximity Read ↗

Real-World Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir in Treatment Naive and Experienced Chronic Hepatitis C Patients: A Single-Center ExperienceSemantic proximity Read ↗

Eight versus twelve weeks of sofosbuvir-velpatasvir in treatment-naïve non-cirrhotic patients with chronic hepatitis C virus infection: Study protocol for a multicentric, open labelled, randomized, non-inferiority trial (RESOLVE trial).Semantic proximity Read ↗

Real World Efficacy and Safety of Sofosbuvir + Velpatasvir + Voxilaprevir in Romanian Patients with Genotype 1b HCV Infection Non-reponders to DAAs Therapy.Semantic proximity Read ↗

Direct-acting antiviral therapy for hepatitis C: The initial experience of the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa.Semantic proximity Read ↗

Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-Saharan Africa.Semantic proximity Read ↗

Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study.Semantic proximity Read ↗

Highly Diverse Hepatitis C Strains Detected in Sub‐Saharan Africa Have Unknown Susceptibility to Direct‐Acting Antiviral TreatmentsSemantic proximity Read ↗

Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.